These companies have strategies, including Anavex. Just not the one you hope about meticulously timing things to make your shares rise in incremental value.
For example, they choose what indications to pursue, when and in what order. They consider finite resources, likelihood of advancement, and several other important factors. And as time is money, they do their best to do it quickly, under those resource constraints, all the while under heavy regulatory and scientific requirements and the uncertainties of site involvement, enrollment pace, CRO performance, and result outcomes. It's why they give milestones like "mid 2020” and not mm dd yyyy, and make conditional statements like "should the trial succeed, we will then proceed to...".
We made an equity investment in a company trying to develop experimental drugs, a very risky and difficult enterprise.